

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/830,946 08/22/2001		Charles Chauveau	C1190/20008	5350
7	590 06/03/2002	i		
Caesar Rivise Bernstein Cohen & Pokotilow Seven Penn Center 12th Floor		•	EXAMINER	
		, ,	GOLLAMUDI,	GOLLAMUDI, SHARMILA S
1635 Market S Philadelphia, P	treet A 19103-2212	•	ART UNIT	PAPER NUMBER
, ,		1	1616	0
			DATE MAILED: 06/03/2002	9

Please find below and/or attached an Office communication concerning this application or proceeding.

<u> </u>		Application No.	Applicant(s)				
Office Action Summary		09/830,946	CHAUVEAU ET AL.				
		Examiner	Art Unit				
		Sharmila S. Gollamudi	1616				
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
Period for Reply							
THE I - Externafter - If the - If NC - Failu - Any i	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Period for reply specified above is less than thirty (30) days, a reply operiod for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be ti within the statutory minimum of thirty (30) da will apply and will expire SIX (6) MONTHS fron cause the application to become ABANDONI	mely filed ys will be considered timely. n the mailing date of this communication. ED (35 U.S.C. § 133).				
1)⊠	Responsive to communication(s) filed on 18 h	March 2002 .	,				
2a)⊠	This action is <b>FINAL</b> . 2b) This	is action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is							
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. <b>Disposition of Claims</b>							
4) Claim(s) 21-47 is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6)⊠	6)⊠ Claim(s) <u>21-47</u> is/are rejected.						
7)	Claim(s) is/are objected to.						
	Claim(s) are subject to restriction and/or	r election requirement.					
· · _	on Papers		1				
9) The specification is objected to by the Examiner.							
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
11)[] :	Applicant may not request that any objection to the	• • •	` ,				
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.  If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
•	under 35 U.S.C. §§ 119 and 120						
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
	☐ All b)☐ Some * c)☐ None of:						
	1. Certified copies of the priority documents	s have been received.					
	Certified copies of the priority documents		tion No.				
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.  14) Asknowledgment is made of a claim for domestic priority under 35 U.S.C. & 110(a) (to a provisional application)							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  a) The translation of the foreign language provisional application has been received.							
15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
2) Notic	te of References Cited (PTO-892) te of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal	ry (PTO-413) Paper No(s) Patent Application (PTO-152)				

U.S. Patent and Trademark Office PTO-326 (Rev. 04-01) Application/Control Number: 09/830,946

Art Unit: 1616

#### **DETAILED ACTION**

Amendment A filed on March 18, 2002 is acknowledged.

Claims 21-47 are included in the prosecution of this application.

# Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Rejection of claims 9-20 under 35 U.S.C. 103(a) as being unpatentable over Ghanta et al (5814332) by itself or in view of Gergely et al (5064656) are maintained.

### Response to Arguments

Applicant argues that Ghanta et al teaches a chewable tablet that contains encapsulated ibuprofen. Applicant argues that Gergely et al does not teach a coated active principle and the dissolution time measured, is dissolution time in water. Further, the applicant argues that Gergely's tablet does not have the same mode of administer.

Applicant's arguments have been fully considered but they are not persuasive. Instant claims recite a tablet that disintegrates in contact with the saliva in the mouth. This language does not exclude the mastication process during disintegration. The reference teaches the presence of rapid disintegrating agents; therefore one of ordinary skill in the art would expect rapid disintegration upon contact with saliva. Additionally, the encapsulation of the active principle is similar to the coating of the active principle in

Application/Control Number: 09/830,946

Art Unit: 1616

the instant invention. In regards to Gergely et al, the examiner points out that instant claims and the independent claims do not state the coating material and Gergely teaches two reactants can be coated with disintegrating agents on column 13, lines 49. Furthermore, Gergely is used to show that proportions can be manipulated to yield the desired dissolution time.

Rejection of claims 9-20 under 35 U.S.C. 103(a) as being unpatentable over Geyer et al (5320848) in view of Meyers et al (5567439) are maintained.

## Response to Arguments

Applicant argues that Geyer et al teaches an active principle in an uncured matrix, which is molded and then compacted.

Applicant's arguments have been fully considered but they are not persuasive.

The instant claim language does not exclude the matrix in the tablet. Furthermore, the instant claims are towards a tablet composition and not the method of making the tablet; therefore the process of molding the tablet or compacting it with excipients does exclude Geyer et al as prior art since Geyer et al teaches the instant agents in a rapid disintegrating tablet.

#### Conclusion

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not

Application/Control Number: 09/830,946

Art Unit: 1616

Page 4

mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

SSG May 22, 2002

JOSÉ G. DEES

SUPERVISORY PATENT EXAMINER

16/6